Page last updated: 2024-11-08

isobavachin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isobavachin: RN given for (S)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID193679
CHEMBL ID491534
CHEBI ID186172
MeSH IDM0443033

Synonyms (15)

Synonym
31524-62-6
isobavachin
CHEMBL491534
(2s)-7-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
CHEBI:186172
S9256
AC-35022
HY-N0762
HMS3886L20
CCG-267745
CS-0009788
MS-24834
7-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-4h-1-benzopyran-4-one
DTXSID20953509
AKOS040757105

Research Excerpts

Overview

Isobavachin is a dietary flavanone with multiple biological activities.

ExcerptReferenceRelevance
"Isobavachin is a dietary flavanone with multiple biological activities. "( An integrated in vitro/in silico approach to assess the anti-androgenic potency of isobavachin.
Huang, S; Luo, H; Ren, L; Shao, C; Zhang, J; Zhao, J, 2023
)
2.58

Pharmacokinetics

ExcerptReferenceRelevance
" The developed method was applied to evaluating the pharmacokinetic study of 13 bioactive compounds after oral administration of Psoraleae Fructus in rat of different genders."( Simultaneous characterization of multiple Psoraleae Fructus bioactive compounds in rat plasma by ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry for application in sex-related differences in pharmacokinetics.
Cheng, LY; Song, L; Wu, YL; Yang, L; Yu, YL; Zhang, Y; Zhou, K; Zhou, ZX, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
flavanonesMembers of the class of flavans with a 3,4-dihydro-2-aryl-2H-1-benzopyran-4-one skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID378957Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID1238084Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at IC50 by MTT assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Chemical constituents isolated from the Mongolian medicinal plant Sophora alopecuroides L. and their inhibitory effects on LPS-induced nitric oxide production in RAW 264.7 macrophages.
AID422533Cytotoxicity against NHEM cells assessed as cell viability 24 hrs by WST-8 assay2009Journal of natural products, Jan, Volume: 72, Issue:1
Melanin synthesis inhibitors from Lespedeza cyrtobotrya.
AID378959Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID378956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID378961Inhibition of TPA-induced EBV-early antigen activation in human Raji cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID1238082Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess method2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Chemical constituents isolated from the Mongolian medicinal plant Sophora alopecuroides L. and their inhibitory effects on LPS-induced nitric oxide production in RAW 264.7 macrophages.
AID422532Inhibition of melanin synthesis in NHEM after 24 hrs by liquid scintillation2009Journal of natural products, Jan, Volume: 72, Issue:1
Melanin synthesis inhibitors from Lespedeza cyrtobotrya.
AID378962Scavenging activity against (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide-induced NO generation in human Chang liver cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID378960Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID378958Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's3 (25.00)24.3611
2020's5 (41.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.87 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]